Devices Personnel

 News Release - May 24, 2010

IDEV Technologies Names Veteran Healthcare Executive Dennis Donohoe, M.D. Chief Medical Officer

Provides Significant and Broad Expertise in Clinical Trials, Regulatory Affairs

WEBSTER, Texas, May 24 -- (Healthcare Sales & Marketing Network) -- IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that veteran healthcare executive Dennis Donohoe, M.D., has been named Chief Medical Officer. Dr. Donohoe reports directly to President and Chief Executive Officer Christopher Owens.

Dr. Donohoe worked in various capacities within Johnson & Johnson for 20 years, 11 of which were with the Cordis division. While with Cordis he had worldwide responsibility for clinical research, encompassing coronary, endovascular and neurovascular products. He ultimately served as Worldwide Vice President of Clinical and Medical Affairs. Dr. Donohoe's expertise has been influential in IDEV's clinical trial efforts, including SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery), a prospective, single-arm trial of 258 patients at a variety of U.S. sites.

"I have worked closely with Dennis over the years and have seen first-hand the value he brings to an organization," said Gary Ansel, M.D., Director, Center for Critical Limb Care, Riverside Methodist Hospital, Columbus, Ohio. "In particular, he will be a major asset in the advancement of IDEV's clinical trials, its relationships with the FDA and other regulatory agencies worldwide."

At IDEV, Dr. Donohoe will manage the Company's clinical group and will provide input to all of the clinical, regulatory and quality control processes and strategies. His expertise will directly contribute to the enhanced growth of the organization, Owens noted.

"Dennis is a world class leader, well known by many healthcare professionals, including the FDA,"
   Owens said. "He will help guide the organization on regulatory and clinical strategies, encompassing both our current and new clinical trials and the launches of our novel and proprietary stent designs and delivery systems in the coming weeks and months. His support and insight, based on his multifaceted professional and medical experience, makes him an invaluable member of our team," Owens said.

Prior to Cordis, Dr. Donohoe worked for seven years at Ethicon where he became Director of Medical Affairs. From 1989 to 1990 he was Associate Director, Gastroenterology for Glaxo, Inc. From 1986 to 1989 he worked in clinical research for McNeil Pharmaceuticals.

Dr. Donohoe is a magna cum laude graduate of LaSalle University and received his M.D. from Milton S. Hershey Medical Center, Penn State University. He did his internship and residency in Family Medicine at Bryn Mawr Hospital.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDEV's worldwide headquarters is located in Webster, Texas and the European headquarters is located in Beuningen, Netherlands.

Source: IDEV Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.